Facile construction of bioreducible crosslinked polypeptide micelles for enhanced cancer combination therapy

Ruttala, Hima Bindu; Chitrapriya, Natarajan; Kaliraj, Kaliappan; Ramasamy, Thiruganesh; Shin, Woo Hyun; Jeong, Jee–Heon; Kim, Jae Ryong; Ku, Sae Kwang; Choi, Han‐Gon; Yong, Chul Soon; Kim, Jong Oh

doi:10.1016/j.actbio.2017.09.002

Cited by 73 publications

(39 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cells treated with combination of SMV+miR-21i showed significantly lower cell viability compared to that of free SMV. Our results clearly highlight the importance of simultaneous interaction of [24,25].…”

Section: Discussionsupporting

confidence: 63%

MicroRNA-21 inhibitor (miR-21i) and Simvastatin-loaded poly (D,L-lactide-co-glycolide)/polyethylenimine (PLGA/PEI) nanoparticles for synergistic anticancer effect in Gastric Cancers

Liu

Yang

Zhang

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: In this study, we have successfully developed a simvastatin (SMV) and miR-21i-loaded poly (D,L-lactide-co-glycolide)/polyethylenimine (PLGA/PEI) nanoparticles (NP) to enhance the therapeutic efficacy in gastric cancers. Methods: The PLGA/PEI nanoparticles by sonication method. The nanoparticles were characterized for in vitro physicochemical and biological assays and pharmacokinetic study was performed in rats. Results: CLSM/FACS results clearly showed the ability of SMV/miR-21i-loaded PLGA/PEI NP (PPN-S21i) to deliver the combinational therapeutics of SMV and miR-21i to the cancer cells. Combination of SMV+miR-21i showed significantly lower cell viability compared to that of free SMV. Our results clearly highlight the importance of simultaneous interaction of SMV+miR-21i and that it could significantly decrease the cell proliferation in BGC-823, SGC-7901 and HGC-27 gastric cancer cells while it was significantly less cytotoxic to normal gastric mucosa cells (GES-1). Cell apoptosis of SMV+miR-21i was significantly higher compared to that of individual drug or miRNA. Finally, pharmacokinetic analysis revealed that PPN-S21i significantly prolonged the blood circulation time of SMV compared to that of free SMV indicating the potential of carrier system. Conclusion: Overall, results clearly indicate that the combination of SMV+miR-21i (gene + drug therapy) might provide a valuable strategy for the clinical management of gastric cancers.

show abstract

Section: Discussionsupporting

confidence: 63%

MicroRNA-21 inhibitor (miR-21i) and Simvastatin-loaded poly (D,L-lactide-co-glycolide)/polyethylenimine (PLGA/PEI) nanoparticles for synergistic anticancer effect in Gastric Cancers

Liu

Yang

Zhang

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…The findings from this study indicated that drug-loaded PMs achieve greater levels in tumor tissues compared to the free drug [ 108 ]. Ruttala et al (2017) developed pH- and redox-responsive crosslinked polypeptide-based micelles for enhanced chemotherapeutic efficacy and minimized side effects through increased stability and drug release properties [ 109 ]. The crosslinked micelles, carrying DTX and lonidamine (LND), exhibited a significantly greater anticancer effect compared to that of non-crosslinked micelles; this method ultimately increased the intracellular ROS level and oxidative stress and caused damage to intracellular components that resulted in greater apoptosis of cancer cells than when either DTX or LND was used alone.…”

Section: Types Of Nps Used For Combination Therapymentioning

confidence: 99%

Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer

Gurunathan

Kang

Qasim

et al. 2018

IJMS

271

133

View full text Add to dashboard Cite

Cancer represents a group of heterogeneous diseases characterized by uncontrolled growth and spread of abnormal cells, ultimately leading to death. Nanomedicine plays a significant role in the development of nanodrugs, nanodevices, drug delivery systems and nanocarriers. Some of the major issues in the treatment of cancer are multidrug resistance (MDR), narrow therapeutic window and undesired side effects of available anticancer drugs and the limitations of anticancer drugs. Several nanosystems being utilized for detection, diagnosis and treatment such as theranostic carriers, liposomes, carbon nanotubes, quantum dots, polymeric micelles, dendrimers and metallic nanoparticles. However, nonbiodegradable nanoparticles causes high tissue accumulation and leads to toxicity. MDR is considered a major impediment to cancer treatment due to metastatic tumors that develop resistance to chemotherapy. MDR contributes to the failure of chemotherapies in various cancers, including breast, ovarian, lung, gastrointestinal and hematological malignancies. Moreover, the therapeutic efficiency of anticancer drugs or nanoparticles (NPs) used alone is less than that of the combination of NPs and anticancer drugs. Combination therapy has long been adopted as the standard first-line treatment of several malignancies to improve the clinical outcome. Combination therapy with anticancer drugs has been shown to generally induce synergistic drug actions and deter the onset of drug resistance. Therefore, this review is designed to report and analyze the recent progress made to address combination therapy using NPs and anticancer drugs. We first provide a comprehensive overview of the angiogenesis and of the different types of NPs currently used in treatments of cancer; those emphasized in this review are liposomes, polymeric NPs, polymeric micelles (PMs), dendrimers, carbon NPs, nanodiamond (ND), fullerenes, carbon nanotubes (CNTs), graphene oxide (GO), GO nanocomposites and metallic NPs used for combination therapy with various anticancer agents. Nanotechnology has provided the convenient tools for combination therapy. However, for clinical translation, we need continued improvements in the field of nanotechnology.

show abstract

“…However, the poor water solubility of taxanes limits their clinical success. DTX, a semisynthetic taxane, binds, and stabilizes microtubules by inducing G2/M arrest, thus interrupts cell division and inhibits tumor growth [ 83 , 84 ]. However, the clinical application of DTX has been hampered due to a number of harmful reactions, including anaphylaxis, neurotoxicity, neutropenia, peripheral neuropathy, and musculoskeletal toxicity [ 85 ].…”

Section: Encapsulation Of Anti-cancer Drugs With Npsmentioning

confidence: 99%

Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies

Wei

Lau

2020

Cancers

View full text Add to dashboard Cite

Conventional chemotherapy is still an important option of cancer treatment, but it has poor cell selectivity, severe side effects, and drug resistance. Utilizing nanoparticles (NPs) to improve the therapeutic effect of chemotherapeutic drugs has been highlighted in recent years. Nanotechnology dramatically changed the face of oncology by high loading capacity, less toxicity, targeted delivery of drugs, increased uptake to target sites, and optimized pharmacokinetic patterns of traditional drugs. At present, research is being envisaged in the field of novel nano-pharmaceutical design, such as liposome, polymer NPs, bio-NPs, and inorganic NPs, so as to make chemotherapy effective and long-lasting. Till now, a number of studies have been conducted using a wide range of nanocarriers for the treatment of solid tumors including lung, breast, pancreas, brain, and liver. To provide a reference for the further application of chemodrug-loaded nanoformulations, this review gives an overview of the recent development of nanocarriers, and the updated status of their use in the treatment of several solid tumors.

show abstract

Facile construction of bioreducible crosslinked polypeptide micelles for enhanced cancer combination therapy

Cited by 73 publications

References 53 publications

MicroRNA-21 inhibitor (miR-21i) and Simvastatin-loaded poly (D,L-lactide-co-glycolide)/polyethylenimine (PLGA/PEI) nanoparticles for synergistic anticancer effect in Gastric Cancers

MicroRNA-21 inhibitor (miR-21i) and Simvastatin-loaded poly (D,L-lactide-co-glycolide)/polyethylenimine (PLGA/PEI) nanoparticles for synergistic anticancer effect in Gastric Cancers

Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer

Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies

Contact Info

Product

Resources

About